Chemistry:Zelebrudomide
From HandWiki
Zelebrudomide (NX-2127) is an investigational new drug that is being evaluated by Nurix Therapeutics for the treatment of relapsed or refractory B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and Waldenström macroglobulinemia (WM). It is an orally bioavailable proteolysis targeting chimera (PROTAC) designed to degrade Bruton's tyrosine kinase (BTK) along with the immunomodulatory proteins Ikaros (IKZF1) and Aiolos (IKZF3).[1][2]
References
- ↑ "BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL". Cancers 17 (3): 557. February 2025. doi:10.3390/cancers17030557. PMID 39941922.
- ↑ "Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies". Journal of Medicinal Chemistry 67 (4): 2321–2336. February 2024. doi:10.1021/acs.jmedchem.3c01007. PMID 38300987.
 |  |
